| 000 | 00876 a2200253 4500 | ||
|---|---|---|---|
| 005 | 20250516181634.0 | ||
| 264 | 0 | _c20140716 | |
| 008 | 201407s 0 0 eng d | ||
| 022 | _a2046-8962 | ||
| 024 | 7 |
_a10.4155/ppa.12.40 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aSklan, Alexandra | |
| 245 | 0 | 0 |
_aHow high is too high for the threshold on patent utility? _h[electronic resource] |
| 260 |
_bPharmaceutical patent analyst _cJul 2012 |
||
| 300 |
_a237 p. _bdigital |
||
| 500 | _aPublication Type: News | ||
| 650 | 0 | 4 | _aCanada |
| 650 | 0 | 4 |
_aDrug Industry _xlegislation & jurisprudence |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aLegislation, Drug |
| 650 | 0 | 4 |
_aPatents as Topic _xlegislation & jurisprudence |
| 773 | 0 |
_tPharmaceutical patent analyst _gvol. 1 _gno. 3 _gp. 237 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.4155/ppa.12.40 _zAvailable from publisher's website |
| 999 |
_c23270727 _d23270727 |
||